(Q35585458)

9 August 2017

Resistant social anxiety disorder response to Escitalopram (English)

1 reference

9 August 2017

social anxiety disorder

1 reference

1 reference

Stefano Pallanti

1

1 reference

PubMed ID

17166264

9 August 2017

Leonardo Quercioli

series ordinal

2

1 reference

9 August 2017

13 December 2006

1 reference

Clinical Practice and Epidemiology in Mental Health

9 August 2017

1 reference

9 August 2017

2

1 reference

9 August 2017

35

1 reference

https://scigraph.springernature.com/pub.10.1186/1745-0179-2-35

9 August 2017

0 references

cites work

Social phobia symptoms: prevalence, sociodemographic correlates, and overlap with specific phobia symptoms

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1769378

Adult life behavioral consequences of early maternal separation are alleviated by escitalopram treatment in a rat model of depression

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1769378

Escitalopram for the treatment of GAD: efficacy across different subgroups and outcomes

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1769378

Optimizing treatment in social phobia: a review of treatment resistance.

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1769378

Citalopram for social anxiety disorder: an open-label pilot study in refractory and nonrefractory patients.

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1769378

The evidence-based pharmacological treatment of social anxiety disorder

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1769378

Efficacy of paroxetine for relapse prevention in social anxiety disorder: a 24-week study

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1769378

Therapeutic advances: paroxetine for the treatment of social anxiety disorder

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1769378

Paroxetine in social phobia/social anxiety disorder. Randomised, double-blind, placebo-controlled study. Paroxetine Study Group

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1769378

The onset of effect for escitalopram and its relevance for the clinical management of depression.

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1769378

Treatment of generalized anxiety disorder with escitalopram: pooled results from double-blind, placebo-controlled trials

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1769378

Escitalopram in the treatment of social anxiety disorder: randomised, placebo-controlled, flexible-dosage study

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1769378

Efficacy and tolerability of escitalopram in 12- and 24-week treatment of social anxiety disorder: randomised, double-blind, placebo-controlled, fixed-dose study

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1769378

Fluvoxamine-controlled release formulation for the treatment of generalized social anxiety disorder

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1769378

Citalopram challenge in social anxiety disorder

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1769378

R-citalopram counteracts the effect of escitalopram in a rat conditioned fear stress model of anxiety

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1769378

Escitalopram (10-20 mg/day) is effective and well tolerated in a placebo-controlled study in depression in primary care

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1769378

Efficacy of citalopram and moclobemide in patients with social phobia: some preliminary findings

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1769378

Effects of escitalopram on anxiety symptoms in depression

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1769378

Treatment of social anxiety disorder with citalopram

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1769378

A Norwegian psychiatric epidemiological study

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1769378

Paroxetine in the treatment of generalized social phobia: open-label treatment and double-blind placebo-controlled discontinuation.

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1769378

Paroxetine in social anxiety disorder: a randomized placebo-controlled study

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1769378

26 September 2018

Identifiers

DOI

10.1186/1745-0179-2-35

1 reference

PubMed ID

17166264

Dimensions Publication ID

9 August 2017

0 references

1 reference

9 August 2017

1 reference

PubMed ID

17166264